Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab and Concurrent Radiochemotherapy in ES-SCLC
NCT06236997Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Feb 2024
- Primary completion
- May 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in small cell lung cancer (SCLC), sponsored by Henan Cancer Hospital. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06236997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06236997.